Skip to main content

Advertisement

Table 1 Clinical and immunophenotypical characteristics of DLBCL patients

From: Prohibitin (PHB) expression is associated with aggressiveness in DLBCL and flavagline-mediated inhibition of cytoplasmic PHB functions induces anti-tumor effects

Features No. of Patients (%)
Age (years) 62
 < 60 31 (38)
 ≥ 60 51 (62)
Sex Male/Female 48 /34 (59/41)
IPI
 0–2 42 (51)
 ≥ 3 40 (49)
IPI Age adjusted (IPIaa)
 0 17 (21)
 1 27 (33)
 2 20 (24)
 3 18 (22)
Ann Arbor stage
 I/II 29 (35)
 III/IV 53 (65)
Serum lactate dehydrogenase (>1x normal) 41 (51)
Pathological type
 GCB 49 (60)
 Non-GCB 33 (40)
Therapy regimen R-CHOP
Median follow-up time, months 53.7 (0.4–202.6)
5-year OS 65.9
5-year PFS 60.6